Matrix extracellular phosphoglycoprotein: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}}))
 
(One intermediate revision by one other user not shown)
Line 6: Line 6:


==References==
==References==
{{reflist}}
{{reflist|2}}


==Further reading==
==Further reading==
Line 23: Line 23:
{{refend}}
{{refend}}


{{gene-4-stub}}
<!-- The PBB_Controls template provides controls for Protein Box Bot, please see Template:PBB_Controls for details. -->
{{PBB_Controls
{{PBB_Controls
| update_page = yes  
| update_page = yes  

Latest revision as of 19:28, 4 September 2012

WikiDoc Resources for Matrix extracellular phosphoglycoprotein

Articles

Most recent articles on Matrix extracellular phosphoglycoprotein

Most cited articles on Matrix extracellular phosphoglycoprotein

Review articles on Matrix extracellular phosphoglycoprotein

Articles on Matrix extracellular phosphoglycoprotein in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Matrix extracellular phosphoglycoprotein

Images of Matrix extracellular phosphoglycoprotein

Photos of Matrix extracellular phosphoglycoprotein

Podcasts & MP3s on Matrix extracellular phosphoglycoprotein

Videos on Matrix extracellular phosphoglycoprotein

Evidence Based Medicine

Cochrane Collaboration on Matrix extracellular phosphoglycoprotein

Bandolier on Matrix extracellular phosphoglycoprotein

TRIP on Matrix extracellular phosphoglycoprotein

Clinical Trials

Ongoing Trials on Matrix extracellular phosphoglycoprotein at Clinical Trials.gov

Trial results on Matrix extracellular phosphoglycoprotein

Clinical Trials on Matrix extracellular phosphoglycoprotein at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Matrix extracellular phosphoglycoprotein

NICE Guidance on Matrix extracellular phosphoglycoprotein

NHS PRODIGY Guidance

FDA on Matrix extracellular phosphoglycoprotein

CDC on Matrix extracellular phosphoglycoprotein

Books

Books on Matrix extracellular phosphoglycoprotein

News

Matrix extracellular phosphoglycoprotein in the news

Be alerted to news on Matrix extracellular phosphoglycoprotein

News trends on Matrix extracellular phosphoglycoprotein

Commentary

Blogs on Matrix extracellular phosphoglycoprotein

Definitions

Definitions of Matrix extracellular phosphoglycoprotein

Patient Resources / Community

Patient resources on Matrix extracellular phosphoglycoprotein

Discussion groups on Matrix extracellular phosphoglycoprotein

Patient Handouts on Matrix extracellular phosphoglycoprotein

Directions to Hospitals Treating Matrix extracellular phosphoglycoprotein

Risk calculators and risk factors for Matrix extracellular phosphoglycoprotein

Healthcare Provider Resources

Symptoms of Matrix extracellular phosphoglycoprotein

Causes & Risk Factors for Matrix extracellular phosphoglycoprotein

Diagnostic studies for Matrix extracellular phosphoglycoprotein

Treatment of Matrix extracellular phosphoglycoprotein

Continuing Medical Education (CME)

CME Programs on Matrix extracellular phosphoglycoprotein

International

Matrix extracellular phosphoglycoprotein en Espanol

Matrix extracellular phosphoglycoprotein en Francais

Business

Matrix extracellular phosphoglycoprotein in the Marketplace

Patents on Matrix extracellular phosphoglycoprotein

Experimental / Informatics

List of terms related to Matrix extracellular phosphoglycoprotein

Matrix, extracellular phosphoglycoprotein with ASARM motif (bone), also known as MEPE, is a human gene.[1]

Phosphatonins have a role in phosphate homeostasis and the relationship between phosphate handling by the kidney and gastrointestinal tract. Matrix extracellular phosphoglycoprotein (MEPE), one of several candidate phosphatonins, promotes phosphaturia.[2] Short-term infusion of MEPE inhibits phosphate absorption in the jejunum but not the duodenum.[2] The phosphaturic action of MEPE may correlate with a significant reduction in renal sodium-phosphate co-transporter NaPi-IIa in the proximal convoluted tubules of the outer renal cortex.[2] This short-term inhibitory effect of MEPE on renal and intestinal phosphate handling occurs without changes in the circulating levels of parathyroid hormone (PTH), 1,25-dihydroxyvitamin D(3), or fibroblast growth factor 23 (FGF23).[2] MEPE may be involved in phosphate homeostasis, acting in both the kidney and the gastrointestinal tract.[2]

References

  1. "Entrez Gene: MEPE matrix, extracellular phosphoglycoprotein with ASARM motif (bone)".
  2. 2.0 2.1 2.2 2.3 2.4 Marks J, Churchill LJ, Debnam ES, Unwin RJ (2008). "Matrix extracellular phosphoglycoprotein inhibits phosphate transport". J Am Soc Nephrol. 19 (12): 2313–20. PMID 19005008. Unknown parameter |month= ignored (help)

Further reading

  • Quarles LD (2003). "FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization". Am. J. Physiol. Endocrinol. Metab. 285 (1): E1–9. doi:10.1152/ajpendo.00016.2003. PMID 12791601.
  • Ogbureke KU, Fisher LW (2005). "Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs)". Kidney Int. 68 (1): 155–66. doi:10.1111/j.1523-1755.2005.00389.x. PMID 15954904.
  • Ogbureke KU, Fisher LW (2004). "Expression of SIBLINGs and their partner MMPs in salivary glands". J. Dent. Res. 83 (9): 664–70. doi:10.1177/154405910408300902. PMID 15329369.
  • Jain A, Fedarko NS, Collins MT; et al. (2004). "Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density". J. Clin. Endocrinol. Metab. 89 (8): 4158–61. doi:10.1210/jc.2003-032031. PMID 15292364.
  • Nampei A, Hashimoto J, Hayashida K; et al. (2005). "Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone". J. Bone Miner. Metab. 22 (3): 176–84. doi:10.1007/s00774-003-0468-9. PMID 15108058.
  • MacDougall M, Simmons D, Gu TT, Dong J (2003). "MEPE/OF45, a new dentin/bone matrix protein and candidate gene for dentin diseases mapping to chromosome 4q21". Connect. Tissue Res. 43 (2–3): 320–30. doi:10.1080/713713461. PMID 12489176.
  • Argiro L, Desbarats M, Glorieux FH, Ecarot B (2001). "Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone". Genomics. 74 (3): 342–51. doi:10.1006/geno.2001.6553. PMID 11414762.
  • Rowe PS, de Zoysa PA, Dong R; et al. (2000). "MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia". Genomics. 67 (1): 54–68. doi:10.1006/geno.2000.6235. PMID 10945470.